KR920702359A - 치료용 헤테로사이클 화합물 - Google Patents

치료용 헤테로사이클 화합물

Info

Publication number
KR920702359A
KR920702359A KR1019920700284A KR920700284A KR920702359A KR 920702359 A KR920702359 A KR 920702359A KR 1019920700284 A KR1019920700284 A KR 1019920700284A KR 920700284 A KR920700284 A KR 920700284A KR 920702359 A KR920702359 A KR 920702359A
Authority
KR
South Korea
Prior art keywords
compound
formula
general formula
group
vii
Prior art date
Application number
KR1019920700284A
Other languages
English (en)
Other versions
KR100215627B1 (ko
Inventor
알란 던칸 로버트슨
알란 피터 힐
로버트 챠알스 글렌
그림 리챠드 마틴
Original Assignee
원본미기재
더 웰컴 화운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26297174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920702359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909012672A external-priority patent/GB9012672D0/en
Priority claimed from GB919102182A external-priority patent/GB9102182D0/en
Application filed by 원본미기재, 더 웰컴 화운데이션 리미티드 filed Critical 원본미기재
Publication of KR920702359A publication Critical patent/KR920702359A/ko
Application granted granted Critical
Publication of KR100215627B1 publication Critical patent/KR100215627B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음

Description

치료용 헤테로사이클 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 하기 일반식(Ⅰ)의 화합물 및 이것의 염, 용매화합물 및 생리적 작용성 유도체 :
    상기식에서, n은 0내지 3의 정수이고: w은 다음 일반식 (ⅰ), (ⅱ) 또는 (ⅲ)의 그룹이고,
    여기에서, R은 C1-4알킬이고, X는 -O-, -S-, -NH-, 또는 -CH2-이고, Y는 산소 또는 황이고 일반식 (ⅰ) 또는 (ⅱ)에서의 비대칭 중심 *은 그것의 (S) 또는 (R)형태이거나 또는 이들의 어떠한 비율의 혼합물이고, 및 Z는 다음 일반식 (ⅳ), (ⅴ) 또는 (ⅳ)의 그룹이고,
    여기서, R1및 R2는 각각 수소 및 C1-4알킬로 부터 선택되고 R3는 수소 또는 C1-4알킬이다.
  2. 제1항에 있어서, n이 1이거나, 또는 W이 일반식 (ⅰ)의 그룹이거나, 또는 Z가 일반식 (ⅳ) 또는 (ⅳ)의 그룹인 일반식 (Ⅰ)의 화합물 및 이것의 생리학적으로 허용가능한 염, 용매화물 및 생리적 작용성 유도체.
  3. 제1항에 있어서, n이 1이고, W은 R이 수소이고, X가 -O-이고 Y가 산소인 일반식 (ⅰ)의 그룹이고, 및 Z는 R1=R2=수소 또는 메틸인 일반식 (ⅳ) 또는 (ⅵ)의 그룹인 일반식 (Ⅰ)의 화합물 및 이것의 생리학적으로 허용가능한 염, 용매화물 및 생리적 작용성 유도체.
  4. 제1항에 있어서, (S) 또는 (R)의 형태 또는 이들의 어떠한 비율의 혼합물로서 N,N-디메틸-2-[5-(2-옥소-1,3-옥사졸리딘-4-일메틸)-1H-인돌-3-일]에틸아민 또는 ;3-(1-메틸-4-피페리딜)-5-(2-옥소-1,3-옥사졸리딘-4-일메틸)-1H-인돌, 또는 이것의 생리학적으로 허용가능한 염, 용매화물 및 생리적 작용성 유도체인 일반식(Ⅰ)의 화합물.
  5. 제4항에 있어서, (S)-N,N-디메틸-2-[5-(2-옥소-1,3-옥사졸리딘-4-일메틸)-1H-인돌-3-일]에틸아민 또는 이것의 생리학적으로 허용가능한 염, 용매화물 및 생리적 작용성 유도체인 일반식(Ⅰ)의 화합물.
  6. 치료제로서 사용하기위한 제1내지 5항중 어느 한항에 따른 일반식 (Ⅰ)의 화합물, 이것의 생리학적으로 허용가능한 염, 용매화물, 또는 생리학적 작용성 유도체.
  7. "5-HT-라이크" 수용체 동근이 나타내어지는 임상학적 상태의 예방 또는 치료에 사용하기 위한, 제1내지 5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물, 이것의 생리학적으로 허용가능한 염, 용매화합물 또는 생리학적 작용성 유도체.
  8. 편두통의 예방 또는 치료에 사용하기 위한 제1 내지 5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물, 이것의 생리학적으로 허용가능한 염, 용매화물 또는 생리학적 작용성 유도체.
  9. "5-HT-라이크" 수용체 동근이 나타내어지는 임상학적 상태의 예방 또는 치료용 약물의 제조시에 제1내지 제5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물, 이것의 생리학적으로 허용가능한 염, 용매화물 또는 생리학적 작용성 유도체를 사용하는 방법.
  10. 편두통의 예방 또는 치료용 약물의 제조시에 제1 내지 5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물, 또는 이것의 생리학적으로 허용 가능한 염, 용매화물, 또는 생리학적 작용성 유도체를 사용하는 방법.
  11. 치료학적으로 유효량의 제1 내지 5항중 어느 한항에 따른 일반식(Ⅰ)화합물, 또는 이것의 생리학적으로 허용가능한 염, 용매화물 또는 생리학적 작용성 유도체를 포유동물에게 투여하는 것을 포함하는 포유류에서 임상학적 상태의 예방 또는 치료방법.
  12. 제11항에 있어서, "5-HT-라이크" 수용체 동근이 나타내어지는 임상학적 상태의 예방 또는 치료방법.
  13. 제12항에 있어서, 편두통의 예방 또는 치료방법.
  14. 제11내지 제13항중 어느 한항에 있어서, 포유동물이 사람인 방법.
  15. 제1내지 제5항중 어느 한항에 따른 일반식(Ⅰ)의 화합물 또는 이것의 생리학적으로 허용가능한 염, 용매화물 또는 생리학적 작용성 유도체, 제약학적으로 허용가능한 담체 및 임의적으로 하나 이상의 다른 생리학적 활성성분을 포함하는 약물.
  16. 제15항에 있어서, 정제 또는 캡슐의 형태인 약품.
  17. (a)Z가 하기 일반식(ⅳ)의 그룹인 경우, 하기 일반식(Ⅱ)의 화합물을, 하기 일반식(Ⅲ)의 화합물 또는 이것의 카르보닐-보호된 형태와 반응시키고, (b)Z가 하기 일반식(Ⅴ)의 구룹인 경우, 일반식(ⅩⅩⅩⅠ)의 화합물을 하기 일반식(ⅩⅩⅧ)의 화합물과 반응시키고, 그리고 (c)Z가 하기 일반식(ⅵ)의그룹인 경우, 일반식(Ⅰ)의 화합물을 환원시키고, W이 하기 일반식(ⅰ) 또는 (ⅱ)의 그룹인 경우에는 하기 일반식(ⅩⅤ) 또는 (ⅩⅩⅤ)의 화합무을 하기 일반식 (Ⅶ)의 화합물과 반응시키고, 임의적으로 이렇게 형성된 일반식(Ⅰ)의 화합물을 대응 하는 염, 용매화물, 생리학적 작용성 유도체로 전환시킴을 포함하는, 하기 일반식(Ⅰ)의 화합물의 제조방법 :
    상기식에서, n은 0내지 13의 정수이고, W은 다음 일반식 (ⅰ), (ⅱ) 또는 (ⅲ)의 그룹이고,
    여기에서, R은 수소 또는 C1-4알킬이고, X는 -O-, -S-, -NH-, 또는 -CH2-이고, Y는 산소 또는 황이고 일반식(ⅰ) 또는 (ⅱ)에서의 비대칭 중심 *은 (S) 또는 (R)형태 도는 이들의 어떠한 비율의 혼합물이고, 및 Z는 하기 일반식 (ⅳ), (ⅴ) 또는 (ⅳ)의 그룹이고,
    여기서, R1및 R2는 각각 수소 및 C1-4알킬로 부터 선택되고 R3는 수소 또는 C1-4이고, L은, 아미노기 또는 -NR1R2로 현장에서 전환될수 있는 적당한 이탈기 또는 보호된 아미노기 이고, 동일 또는 상이할수 있는 L 및 L1은 적당한 이탈기이다.
  18. (a)일반식 (Ⅰ)의 화합물 또는 이것의 생리학적으로 허용가능한 염, 용매화합물, 또는 생리학적 작용성 유도체를 제17항의 방법에 의해 제조하고, (b)단계 (a)로 부터의 생성물을 제약학적으로 허용가능한 담체 및 임의적으로는 하나 이상의 다른 생리학적 활성성분과 혼합함을 포함하는 약물의 제조방법.
  19. 제18항에 있어서, 단계 (b)로 부터의 혼합물을 정제 또는 캡슐로 형성하는 추가의 단계(c)를 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700284A 1990-06-07 1991-06-06 치료용 헤테로사이클 화합물 KR100215627B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9012672-3 1990-06-07
GB909012672A GB9012672D0 (en) 1990-06-07 1990-06-07 Therapeutic heterocyclic compounds
GB9012672.3 1990-06-07
GB9102182-4 1991-02-01
GB919102182A GB9102182D0 (en) 1991-02-01 1991-02-01 Therapeutic heterocyclic compounds
PCT/GB1991/000908 WO1991018897A1 (en) 1990-06-07 1991-06-06 Therapeutic heterocyclic compounds

Publications (2)

Publication Number Publication Date
KR920702359A true KR920702359A (ko) 1992-09-03
KR100215627B1 KR100215627B1 (ko) 1999-08-16

Family

ID=26297174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700284A KR100215627B1 (ko) 1990-06-07 1991-06-06 치료용 헤테로사이클 화합물

Country Status (37)

Country Link
US (3) US5399574A (ko)
EP (2) EP0636623B1 (ko)
JP (1) JP2738461B2 (ko)
KR (1) KR100215627B1 (ko)
AT (2) ATE156823T1 (ko)
AU (1) AU646871B2 (ko)
CA (2) CA2064815C (ko)
CZ (1) CZ288351B6 (ko)
DE (3) DE69127260T2 (ko)
DK (1) DK0486666T3 (ko)
EG (1) EG19650A (ko)
ES (1) ES2104708T3 (ko)
FI (3) FI105686B (ko)
GR (1) GR3024828T3 (ko)
HK (1) HK1000534A1 (ko)
HR (1) HRP940524B1 (ko)
HU (2) HU219974B (ko)
IE (1) IE911931A1 (ko)
IL (3) IL114690A (ko)
LT (1) LT3264B (ko)
LU (1) LU90205I2 (ko)
LV (1) LV10274B (ko)
MC (1) MC2210A1 (ko)
MX (1) MX9203421A (ko)
MY (1) MY110226A (ko)
NL (1) NL980001I2 (ko)
NO (2) NO300634B1 (ko)
NZ (1) NZ238424A (ko)
PL (1) PL166214B1 (ko)
PT (1) PT97888B (ko)
RU (1) RU2160736C2 (ko)
SA (1) SA05260104B1 (ko)
SI (2) SI21560B (ko)
SK (1) SK281621B6 (ko)
UA (1) UA37178C2 (ko)
WO (1) WO1991018897A1 (ko)
YU (1) YU48855B (ko)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (ko) * 1991-02-12 1995-11-21 Pfizer
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (ko) * 1992-03-05 1996-10-11 Pfizer
JP3309982B2 (ja) * 1992-03-13 2002-07-29 メルク シヤープ エンド ドーム リミテツド イミダゾール，トリアゾールおよびテトラゾール誘導体
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
CZ281763B6 (cs) 1992-04-07 1997-01-15 Pfizer Inc. Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
SK278182B6 (en) * 1992-04-10 1996-03-06 Pfizer Acylaminoindole derivatives as 5-ht1 agonists, method of their preparation and pharmaceutical compositions containing these matters their use and semifinished products of preparation proces
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
WO1994002477A1 (en) * 1992-07-24 1994-02-03 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
TW251284B (ko) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
HUT75646A (en) * 1993-08-31 1997-05-28 Pfizer 5-arylindole derivatives and pharmaceutical compositions containing them
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
JPH10501212A (ja) * 1994-05-19 1998-02-03 メルク シヤープ エンド ドーム リミテツド ５−ｈｔ▲下１ｄ▼−アルファ作働薬としてのインドール−３−イルアルキルのピペラジン、ピペリジンおよびテトラヒドロピリジン誘導体
DK0765322T3 (da) * 1994-06-01 2001-10-22 Astrazeneca Ab Indolderivater som pro-drugs for 5-HT1-lignende receptoragonister
JP3155008B2 (ja) * 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
US6025374A (en) * 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
GB9515060D0 (en) * 1995-07-22 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9515305D0 (en) * 1995-07-26 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6909005B1 (en) * 1995-08-07 2005-06-21 Astrazeneca Uk Limited One post synthesis of 2-oxazolidinone derivatives
GB9516143D0 (en) 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
AU7319096A (en) * 1995-11-02 1997-05-22 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
EP1341777B1 (en) * 2000-11-29 2007-09-26 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
DE60317333T2 (de) 2002-06-21 2008-08-28 Suven Life Sciences Ltd. Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
RU2320663C2 (ru) 2002-06-21 2008-03-27 Сувен Лайф Сайенсиз Лимитед Новые арилалкилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
ES2204302B2 (es) 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
PT1581492E (pt) 2002-11-28 2008-09-19 Suven Life Sciences Ltd Indoles n-arilsulfonil-3-substituídos possuindo afinidade de receptor de serotonina, processo para a sua preparação e composição farmacêutica contendo os mesmos
CN1720227A (zh) 2002-11-28 2006-01-11 苏文生命科学有限公司 N－芳基磺酰基－3－氨基烷氧基吲哚
CN100378109C (zh) 2002-12-18 2008-04-02 苏文生命科学有限公司 具有5-羟色胺受体亲和性的四环3-取代的吲哚类化合物
WO2004056769A2 (en) 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
WO2004063175A1 (en) * 2003-01-13 2004-07-29 Natco Pharma Limited A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20040192958A1 (en) * 2003-03-25 2004-09-30 Hyatt John Anthony Process for preparing derivatives of 4-halobutyraldehyde
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
GEP20094676B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
WO2006055964A2 (en) * 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
JP5833804B2 (ja) 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
WO2007083320A2 (en) 2006-01-19 2007-07-26 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
WO2007118314A1 (en) 2006-04-13 2007-10-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
EP2425820B1 (en) * 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CA2833209C (en) 2007-04-27 2016-06-28 Purdue Pharma L.P. Piperidine and piperazine compounds as trpv1 antagonists
US8389549B2 (en) * 2007-04-27 2013-03-05 Purdue Pharma L.P. Substituted pyridines useful for treating pain
JP2010540613A (ja) * 2007-10-03 2010-12-24 ジェネリクス・（ユーケー）・リミテッド ゾルミトリプタン、その塩、及びその溶媒和物の調製方法
EP2220075A4 (en) * 2007-11-16 2012-02-29 Neuraxon Inc INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
CN101181267B (zh) * 2007-11-30 2010-09-08 重庆医科大学医药研究所 佐米曲普坦舌下片
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20110038928A1 (en) * 2009-08-12 2011-02-17 Glenmark Generics Ltd Orally disintegrating tablets of zolmitriptan
BR112013009004B1 (pt) 2010-10-15 2022-05-10 Contera Pharma Aps Uso de composição farmacêutica ou kit de partes compreendendo combinações de agonistas dereceptor de serotonina
AR086709A1 (es) 2011-06-22 2014-01-15 Purdue Pharma Lp Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012287120B2 (en) 2011-07-22 2017-02-23 The University Of Chicago Treatments for migraine and related disorders
WO2013057739A2 (en) * 2011-09-02 2013-04-25 Emcure Pharmaceuticals Limited An improved process for preparation of zolmitriptan
BR112014025907B1 (pt) 2012-04-18 2023-02-14 Contera Pharma Aps Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
EP3407869A1 (en) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB148879A (en) * 1919-02-14 1921-11-10 Emil Vincance Noser Locks for shift levers of automobiles
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US3879410A (en) * 1971-02-08 1975-04-22 Messrs Lab Guidotti & C S P A 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity
BE795457A (fr) * 1972-02-16 1973-08-16 Clin Midy Amines indoliques, leur preparation et leur application en therapeutiques
FR2179582B1 (ko) * 1972-04-13 1975-10-10 Synthelabo
US3873559A (en) * 1973-03-30 1975-03-25 Squibb & Sons Inc Heterocyclic carboxamido thiazolinyl indoles
US4042595A (en) * 1973-08-01 1977-08-16 Snam Progetti S.P.A. Processes for the production of heterocyclic compounds
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
FR2315925A1 (fr) * 1975-07-04 1977-01-28 Nippon Chemiphar Co Nouveaux derives de 5-benzyle-2-oxazolidone, leur procede de preparation et leur application en therapeutique
GB1482879A (en) * 1975-07-24 1977-08-17 Nippon Chemiphar Co 5-benzyl-2-oxazolidone derivatives and a process for producing the same
GB1469200A (en) * 1975-11-28 1977-03-30 Warner Lambert Co 3-thiomethyl-2-2-dialkylamino-ethyl-indoles
DE2557341A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
IT1109002B (it) * 1977-09-22 1985-12-16 Menarini Sas Derivati del 2 oxazolidone e loro metodi di preparazione
US4137404A (en) * 1977-12-20 1979-01-30 Hoffmann-La Roche Inc. Synthesis of tryptophans
US4198501A (en) * 1977-12-20 1980-04-15 Hoffmann-La Roche Inc. Synthesis of tryptophans
JPS6014032B2 (ja) * 1978-01-20 1985-04-11 日本ケミフア株式会社東京 ５‐フエネチル‐２‐オキサゾリドン誘導体およびその製法
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2933636A1 (de) * 1978-08-30 1980-03-20 Sandoz Ag Neue n-phenylindolinderivate, ihre herstellung und pharmazeutische praeparate, welche diese verbindungen enthalten
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4272555A (en) * 1979-09-21 1981-06-09 Monsanto Company Conversion of carbon-containing materials to carbon monoxide
EP0083566A1 (en) * 1980-04-10 1983-07-13 Sandoz Ag Isoxazolyl indoles
JPS574986A (en) * 1980-06-13 1982-01-11 Paamakemu Asia:Kk Preparation of oxazolidine derivative
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
DE3131728A1 (de) * 1980-08-12 1982-03-11 Glaxo Group Ltd., London Indolverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4407811A (en) * 1981-01-02 1983-10-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4448971A (en) * 1981-01-02 1984-05-15 Pfizer Inc. Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones
US4399296A (en) * 1981-01-02 1983-08-16 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS57169458A (en) * 1981-04-13 1982-10-19 Paamakemu Asia:Kk Preparation of indole derivative
CH656124A5 (de) * 1982-04-13 1986-06-13 Sandoz Ag 2-substituierte-3-indolamine, verfahren zu deren herstellung sowie deren verwendung.
GR79215B (ko) * 1982-06-07 1984-10-22 Glaxo Group Ltd
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4500717A (en) * 1983-03-28 1985-02-19 The Dow Chemical Company Process for preparation of 2-oxazolidinones
US4831153A (en) * 1983-06-27 1989-05-16 The Dow Chemical Company Preparation of N-vinyl-2-oxazolidinone
GB8321813D0 (en) * 1983-08-12 1983-09-14 Vickers Plc Radiation sensitive compounds
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
GB2168973B (en) * 1984-12-04 1988-02-03 Glaxo Group Ltd Indole derivatives
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3514696A1 (de) * 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
DE3678805D1 (de) * 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8607824D0 (en) * 1986-03-27 1986-04-30 Glaxo Group Ltd Chemical compounds
DE3643957A1 (de) * 1986-12-22 1988-06-30 Bayer Ag Substituierte n-methylisoxazolidine
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
US4997841A (en) * 1987-08-13 1991-03-05 Glaxo Group Limited Indole derivatives
DE3730777A1 (de) * 1987-09-12 1989-03-23 Basf Ag Verfahren zur herstellung von imidazolidinonen und oxazolidinonen
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
DE68918792T2 (de) * 1988-09-15 1995-03-30 Upjohn Co 5-Indolinyl-5-beta-amidomethyloxazolidin-2-one, 3-(substituierte kondensierte)phenyl-5-beta amidomethyloxazolidin-2-one und 3-(Nitrogen-substituierte)phenyl-5-beta-amidomethyloxazolidin-2-one.
DE3939238A1 (de) * 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4013907A1 (de) * 1990-04-26 1991-10-31 Schering Ag Verfahren zur herstellung von gramin-derivaten
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives

Also Published As

Publication number Publication date
IE20010862A1 (en) 2003-03-05
US5399574A (en) 1995-03-21
CA2064815A1 (en) 1991-12-08
GR3024828T3 (en) 1998-01-30
AU7957091A (en) 1991-12-31
YU101091A (sh) 1994-04-05
HRP940524B1 (en) 1998-10-31
JPH05502679A (ja) 1993-05-13
MC2210A1 (fr) 1992-11-26
CA2064815C (en) 1999-11-16
NL980001I1 (nl) 1998-03-02
MY110226A (en) 1998-03-31
IE911931A1 (en) 1991-12-18
DK0486666T3 (da) 1998-03-30
EP0486666B1 (en) 1997-08-13
SI9111010B (sl) 2005-02-28
NO920494D0 (no) 1992-02-06
FI960155A (fi) 1996-01-12
LV10274B (en) 1995-04-20
HU211479A9 (en) 1995-11-28
DE69127260D1 (de) 1997-09-18
FI105686B (fi) 2000-09-29
LTIP419A (en) 1994-11-25
IL98392A (en) 1996-01-19
NZ238424A (en) 1993-12-23
HU9200384D0 (en) 1992-06-29
IL114690A0 (en) 1995-11-27
DE69132691D1 (de) 2001-09-20
EP0636623A1 (en) 1995-02-01
LU90205I2 (fr) 1998-04-06
CZ288351B6 (en) 2001-05-16
DE69127260T2 (de) 1997-12-04
YU48855B (sh) 2002-06-19
PT97888A (pt) 1992-05-29
LV10274A (lv) 1994-10-20
RU2160736C2 (ru) 2000-12-20
PL166214B1 (pl) 1995-04-28
FI960155A0 (fi) 1996-01-12
HRP940524A2 (en) 1996-06-30
DE19775091I2 (de) 2007-05-24
EP0486666A1 (en) 1992-05-27
NO1998005I1 (no) 1998-01-21
WO1991018897A1 (en) 1991-12-12
UA37178C2 (uk) 2001-05-15
FI20001406A (fi) 2000-06-13
CS172791A3 (en) 1992-02-19
SI21560B (sl) 2005-04-30
ATE156823T1 (de) 1997-08-15
PT97888B (pt) 1998-12-31
CA2282890C (en) 2001-07-31
CA2282890A1 (en) 1991-12-08
IL114690A (en) 1997-02-18
JP2738461B2 (ja) 1998-04-08
FI106262B (fi) 2000-12-29
US5466699A (en) 1995-11-14
AU646871B2 (en) 1994-03-10
EG19650A (en) 1995-09-30
EP0636623B1 (en) 2001-08-16
HUT62289A (en) 1993-04-28
ATE204275T1 (de) 2001-09-15
DE69132691T2 (de) 2002-06-20
SA05260104B1 (ar) 2006-04-04
SI21560A (sl) 2005-02-28
US5863935A (en) 1999-01-26
IL98392A0 (en) 1992-07-15
ES2104708T3 (es) 1997-10-16
NO300634B1 (no) 1997-06-30
MX9203421A (es) 1992-07-01
NL980001I2 (nl) 1998-05-06
KR100215627B1 (ko) 1999-08-16
NO920494L (no) 1992-03-30
SI9111010A (en) 1997-12-31
HU219974B (hu) 2001-10-28
SA05260104A (ar) 2005-12-03
SK281621B6 (sk) 2001-05-10
LT3264B (en) 1995-05-25
FI920503A0 (fi) 1992-02-06
HK1000534A1 (en) 1998-04-03

Similar Documents

Publication Publication Date Title
KR920702359A (ko) 치료용 헤테로사이클 화합물
KR950014445B1 (ko) 세로토닌 길항물질 함유 약화 조성물
RU95112537A (ru) Терапевтические гетероциклические соединения, способ их получения, фармацевтическая композиция, способ ее получения
US20060211603A1 (en) Ramoplanin derivatives possessing antibacterial activity
ES2607084T3 (es) Profármacos de éster de [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil]-metanol para rebajar la presión intraocular
KR890003731A (ko) 인돌 유도체
KR920021523A (ko) 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물
JPH06505725A (ja) ５−フルオロ−２’−デオキシ−３’−チアシチジンのｂ型肝炎治療への使用
KR930010039A (ko) 인돌로피롤로카르바졸 유도체
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JPH10508847A (ja) 酸化窒素合成酵素インヒビターとして有用なアミノテトラゾール誘導体
JPH09501651A (ja) Ｎｏシンターゼ阻害剤としてのアミノ酸誘導体
US7872040B2 (en) Receptor blocker and vasodilator comprising indole derivative as active ingredient
KR880007538A (ko) 피리다조 디아제핀 유도체
OA10189A (en) Use of indole derivatives as 5htl agonists
KR940702491A (ko) 옥사졸리돈 유도체
CN108463463A (zh) 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途
JP2013522321A (ja) Ｈｉｖを治療するためのｃｃｒ５モジュレーター
KR910016691A (ko) 신규한 치환된-아민 화합물 및 그의 제조방법
KR900012925A (ko) 인돌 유도체
AU2001247540B2 (en) Novel benzosultam oxazolidinone antibacterial agents
NL7908101A (nl) Nieuwe farmaceutische preparaten met analgetische, anti-pyretische en/of anti-inflammatore activiteit.
KR920006326A (ko) 새로운 아미노산 유도체, 그것의 제조방법 및 그것을 함유하는 약학적 조성물
JPS6324514B2 (ko)
KR950008509A (ko) 인돌릴알킬-피리디닐 및 피리미디닐피페파라진의 항편두통 사이클로부텐디온 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120503

Year of fee payment: 14

EXPY Expiration of term